Genomic classifier for guiding treatment of intermediate-risk prostate cancers to dose-escalated image-guided radiotherapy without hormone therapy.
Authors
Berlin, AMurgic, J
Hosni, A
Pintilie, M
Salcedo, A
Fraser, M
Kamel-Reid, S
Zhang, J
Wang, Q
Ch'ng, C
Deheshi, S
Davicioni, E
van der Kwast, T
Boutros, P
Bristow, Robert G
Chua, M
Affiliation
Princess Margaret Cancer Centre, University Health Network, Ontario, CanadaIssue Date
2018-08-28
Metadata
Show full item recordAbstract
The NCCN has recently endorsed the stratification of intermediate-risk prostate cancer (IR-PCa) into favorable and unfavourable subgourps, and recommend the addition of androgen deprivation therapy (ADT) to radiotherapy (RT) for unfavorable IR-PCa. Recently, more accurate prognostication was demonstrated by integrating a 22-feature genomic classifier (GC) to the NCCN stratification system. Here, we test the utility of the GC to better identify IR-PCa patients who are sufficiently treated by RT alone.Citation
Genomic classifier for guiding treatment of intermediate-risk prostate cancers to dose-escalated image-guided radiotherapy without hormone therapy. 2018, Int J Radiat Oncol Biol PhysJournal
International Journal of Radiation Oncology, Biology, PhysicsDOI
10.1016/j.ijrobp.2018.08.030PubMed ID
30170099Type
ArticleLanguage
enISSN
1879-355Xae974a485f413a2113503eed53cd6c53
10.1016/j.ijrobp.2018.08.030
Scopus Count
Collections
Related articles
- Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy.
- Authors: Tom MC, Reddy CA, Smile TD, Zhang RX, Ciezki JP, Stephans KL, Mian OY, Klein EA, Campbell S, Ulchaker J, Angermeier K, Tendulkar RD
- Issue date: 2020 Jan-Feb
- Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
- Authors: Falchook AD, Basak R, Mohiuddin JJ, Chen RC
- Issue date: 2016 Aug 1
- Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
- Authors: Amit U, Lawrence YR, Weiss I, Symon Z
- Issue date: 2019 Jun 10
- Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer.
- Authors: Ong WL, Foroudi F, Evans S, Millar J
- Issue date: 2017 Nov
- The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
- Authors: Dong Y, Ruth KJ, Churilla TM, Viterbo R, Sobczak ML, Smaldone MC, Chen DY, Uzzo RG, Hallman MH, Horwitz EM
- Issue date: 2017 Feb